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Background: Advanced non-small cell lung cancer (NSCLC) represents a significant unmet medical need. Despite
advances with targeted therapies in a small subset of patients, fewer than 20% of patients survive for more than two
years after diagnosis. Cancer vaccines are a promising therapeutic approach that offers the potential for durable
responses through the engagement of the patient’s own immune system. CV9202 is a self-adjuvanting mRNA vaccine
that targets six antigens commonly expressed in NSCLC (NY-ESO-1, MAGEC1, MAGEC2, 5 T4, survivin, and MUC1).
Methods/Design: The trial will assess the safety and tolerability of CV9202 vaccination combined with local radiation
designed to enhance immune responses and will include patients with stage IV NSCLC and a response or stable
disease after first-line chemotherapy or therapy with an EGFR tyrosine kinase inhibitor. Three histological and molecular
subtypes of NSCLC will be investigated (squamous and non-squamous cell with/without EGFR mutations). All patients
will receive two initial vaccinations with CV9202 prior to local radiotherapy (5 GY per day for four successive days)
followed by further vaccinations until disease progression. The primary endpoint of the study is the number of patients
experiencing Grade >3 treatment-related adverse events. Pharmacodynamic analyses include the assessment of
immune responses to the antigens encoded by CV9202 and others not included in the panel (antigen spreading) and
standard efficacy assessments.
Discussion: RNActive self-adjuvanted mRNA vaccines offer the potential for simultaneously inducing immune
responses to a wide panel of antigens commonly expressed in tumors. This trial will assess the feasibility of this
approach in combination with local radiotherapy in NSCLC patients.
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Lung cancer is the leading cause of cancer-related mor-
tality in both men and women and the incidence of the
disease is increasing globally [1]. Approximately 85% of
patients with lung cancer have non-small cell lung can-
cer (NSCLC) and 40% of these individuals will have
stage IV metastatic disease at diagnosis [2]. These pa-
tients have a particularly poor prognosis and represent a
significant unmet medical need. The selection of appro-
priate therapy is determined by the histological and mo-
lecular subtype of the disease. Four to six cycles of a
non-pemetrexed-containing platinum-based combination
chemotherapy is the recommended first-line therapy for
fit patients with squamous cell histology, whereas in pa-
tients with non-squamous cell histology, a chemotherapy
combination of pemetrexed and a platinum-based chemo-
therapy is a well-accepted standard of care [3]. However,
the survival benefit with these regimens is modest, with a
median overall survival (OS) of around 10–14 months
[3-6]. Patients with non-squamous tumors harboring acti-
vating epidermal growth factor receptor (EGFR) mutations
achieve impressive response rates when treated with the
EGFR tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib
and afatinib [7-11]. These targeted therapies achieve a me-
dian OS of approximately 2–3 years. Similarly, patients
with tumors containing anaplastic lymphoma receptor
tyrosine kinase (ALK) fusion oncogenes achieve higher re-
sponse rates when treated with the ALK inhibitor crizo-
tinib compared with chemotherapy in patients who haveTable 1 Cancer vaccination approaches investigated in NSCLC
Vaccine Target(s) Indicatio
CIMAVax EGF (recombinant peptide vaccine) EGF Pre-treat
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Recombinant fusion protein of MAGEA3











Belagenpumatucel-L (Lucanix®) TGF-β2 Pre-treat
(Phase II
BSC, best supportive care; DFS, disease-free survival; EGF, epidermal growth factor;
melanoma antigen family A3/C1/C2; NSCLC, non-small cell lung cancer; NY-ESO-1, N
progression-free survival; QoL, quality of life.received prior chemotherapy [12]. However, the effect of
targeted therapies is limited due to the inevitable devel-
opment of resistance, and patients with these driver mu-
tations cannot yet be cured [13]. Therefore, novel and
well-tolerated therapies that improve outcomes for all pa-
tients with NSCLC are clearly needed.
Several types of active immunotherapy are currently
under investigation in NSCLC, including antibodies de-
signed to overcome inhibitory immune signals such as
ipilimumab, which targets the inhibitory CTLA-4 recep-
tor on cytotoxic T-lymphocytes [14], and antibodies that
target the inhibitory programmed death 1 receptor and
its ligand [15]. Stimulating the patient’s own immune
system to attack malignant cells through therapeutic
vaccination against cancer-associated antigens is another
promising approach [16]. Phase II studies have shown
that cancer vaccines are well tolerated in patients with
advanced NSCLC and several therapies have now en-
tered or completed phase III trials (Table 1) [17-24].
RNActive® (CureVac GmbH, Germany) self-adjuvanted
mRNA vaccines are a novel technology in which the
mRNA sequences are optimized to enhance antigen ex-
pression by up to 4-5 orders of magnitude [25,26]. The
vaccine consists of two components: free mRNA and
mRNA complexed with the cationic protein protamine.
This complexed part of the vaccine has been shown to
activate the immune system by involvement of toll-like
receptor (TLR) 7 [25]. This results in a strong and bal-
anced immune response comprising both humoral andn Key results
ed stage IIIB/IV NSCLC
, N = 80) [17]
Improved OS in younger (<60 years of age)
patients compared with BSC alone
ed stage IIIB/IV NSCLC
, N = 88) [18]
Improved QoL compared with BSC
d, unresectable stage III
hase III, N = 1513) [19]
Improved survival in a prespecified stratum
of >800 patients with locoregional stage IIIB
disease treated with concomitant
chemoradiation
ositive stage IIIB or IV
hase IIb, N = 148) [20]




LC (Phase II, N = 182) [21]
All patients receiving the active treatment
showed a humoral immune response to
the MAGEA3 antigen
-positive stages IB, II and
C (Phase III, N = 2278) [22]
Did not extend DFS compared with placebo.
Trial continuing
ed stage IIIB/IV NSCLC
IIa, N = 46) [23]
Antigen-specific immune responses
against ≥1 antigen were induced in 65%
of patients
ed stage IIIA/IIIB/IV NSCLC
I, N = 532) [24]
Improved OS in subset of patients
randomized within 12 weeks of completion
of prior chemotherapy
MUC1, mucin 1, cell surface associated; IL-2, interleukin-2; MAGEA3/C1/C2,
ew York esophageal squamous cell carcinoma 1; OS, overall survival; PFS,
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RNActive vaccines encoding different cancer antigens
have been investigated in two phase I/IIA trials in pa-
tients with advanced prostate cancer and NSCLC where
they were well-tolerated and induced antigen-specific
cellular and humoral immune responses [23,27].
The CV9202 vaccine consists of six mRNAs that code
for six different NSCLC-associated antigens (Table 2).
Three of these mRNAs encode cancer testes antigens
(NY-ESO-1, MAGEC1, and MAGEC2) which are nor-
mally only expressed in male germ cells but are often also
expressed in tumors including NSCLC, making them an
attractive target for cancer vaccines [28]. NY-ESO-1 is one
of the most immunogenic tumor antigens defined to date
and its expression in tumor may correlate with poor sur-
vival [29,30]. The other mRNAs encode 5 T4, survivin and
MUC1. The trophoblast glycoprotein 5 T4 is expressed on
undifferentiated, tumor-initiating cells in NSCLC and pre-
dicts poor clinical outcome [31]. Survivin is commonly
overexpressed in NSCLC and is associated with reduced
survival [32]. With the inclusion of MUC1, which is over-
expressed and abnormally glycosylated on almost all
adenocarcinoma epithelia cells [33], CV9202 also targets
an antigen that has shown promising clinical effects as a
vaccination target in several clinical trials in NSCLC pa-
tients [18-20].
While radiotherapy was historically assumed to be im-
munosuppressive, the release of tumor cell antigens into
the tumor microenvironment following radiotherapy-
induced cell death actually represents a form of im-
munogenic cell death that can stimulate a tumor-specific
immune response [34,35]. This is best supported by the









Melanoma antigen family C 1 MAGEC1 1813 bases
(CT7)
Melanoma antigen family C 2 MAGEC2 1339 bases
(CT10/HCA587)
Baculoviral IAP repeat-containing 5 BIRC5 646 bases
(survivin/API4)
Trophoblast glycoprotein TPBG 1480 bases
(5 T4/5 T4-AG/M6P1)
Mucin 1, cell surface associated MUC1 1885 bases
(PEM)
API4, apoptosis inhibitor 4; CT7/10, Cancer/testis antigen 7/10; CTAG1b,
cancer/testis antigen 1B; HCA587, Hepatocellular Cancer Antigen 587;
PEM, polymorphic epithelial mucin.the irradiation of the primary tumor, the so called
‘abscopal effect’ [36]. A recent clinical case report de-
scribes a regression of non-irradiated metastases in a pa-
tient with metastatic melanoma who had disease
progression during treatment with ipilimumab after ir-
radiation of a mediastinal metastasis with 3 × 9 GY [37].
Immunogenic cell death is characterized by cell surface
translocation of calreticulin and extracellular release of
ATP and the high-mobility-group box 1 (HMGB1) pro-
tein [34,38]. HMGB1 binds to TLR4 expressed on den-
dritic cells and promotes the cross-presentation of
tumor-antigens between dendritic cells and T cells, an
integral part of the immune response [39,40]. Radiother-
apy also induces the release of pro-inflammatory compo-
nents into the tumor microenvironment [41], and
upregulates MHC class 1 molecules on the tumor cells
[42] which further potentiate this response.
Synergism between vaccination or CTLA4 blockade
and radiotherapy has been reported in preclinical models
for both single-dose radiation and fractionated regimens
[43-45]. The synergy between immunotherapies and
radiotherapy may be greater when radiation is given as a
fractionated regimen compared with single dose radio-
therapy – complete primary tumor regression was seen
in mice breast cancer models treated with an anti-CTL4
antibody and fractionated (3 × 8 GY) radiotherapy, but
not in mice treated with antibody alone or antibody with
single-dose radiotherapy [44]. Furthermore, an abscopal
effect was seen only in the mice treated with the frac-
tionated radio-immunotherapy combination [44]. Frac-
tionated regimens may also achieve an optimal balance
between a high level of T cell cross-priming with low in-
duction of Treg cells [46]. Synergism between mRNA
vaccination and fractionated local radiation was seen in
C57BL/6 mice bearing subcutaneous immunogenic
E.G7-OVA tumors (treated with 3–4 × 2 GY) or low im-
munogenic Lewis lung carcinoma cells (treated with frac-
tions of 3 × 12 GY) [CureVac, 47]. In the latter model,
combination treatment resulted in an increased infiltration
of both innate (CD11c dendritic cells, CD11b +myeloid
cells, NK, and NK T cells) and adaptive (CD4+ and CD8+
T cells) tumor-infiltrating immune cells. Given these ob-
servations, local radiation of individual tumor sites in
patients with metastatic cancer may be an effective way
to enhance the systemic antitumor effect of a cancer
vaccine.
The aim of this study is to assess the safety and toler-
ability of the CV9202 vaccine in combination with local
radiation in patients with stage IV NSCLC who achieved
a response or stable disease after first-line therapy, either
with chemotherapy or EGFR TKIs. We have selected a
regimen of 4 × 5 GY, a well-established palliative radi-
ation regimen that can be safely applied to metastatic le-
sions in the lung, bone, and soft tissue [48].
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Study design
Study CV-9202-006 (Trial registration number: NCT
01915524) is an exploratory, open-label multicenter phase
Ib trial of RNActive-derived cancer vaccine and local radi-
ation as consolidation and maintenance treatment in pa-
tients with stage IV NSCLC achieving a response or stable
disease after first-line therapy (chemotherapy or therapy
with an EGFR tyrosine kinase inhibitor). The study will be
conducted according to good clinical practice and the
Declaration of Helsinki and in keeping with local regula-
tions. Written informed consent will be obtained from all
patients before any study-related activities are con-
ducted. This study was approved by the ethics commit-
tees of University Hospital Basel, Kantonsspital St Gallen,
Kantonsspital Winterthur, and Kantonsspital Graubünden
in Switzerland; University Hospital Mainz and UniversityTable 3 Inclusion and exclusion criteria
Criteria Details
Inclusion criteria • Histologically or cytologically-confirmed meta
• ≥18 years of age
• Presence of at least one tumor lesion ≥ 2 cm
tumor lesion according to RECIST Ver 1.1
• ECOG performance status 0 to 1
• Adequate organ function: hemoglobin ≥95 g/
neutrophil count ≥1000/μL, lymphocyte coun
metastases and ≤5 times ULN in patients with
≥45 mL/min according to MDRD formula
Exclusion criteria • Previous active immunotherapy for NSCLC (in
• Treatment with any investigational product in
• Need for immunosuppressive treatment
• Active skin disease not allowing intradermal in
(for stratum 3 patients: persisting grade 3 skin
• Inadequate lung function dependent on the i
(for patient planned to undergo radiation of t
• Prior splenectomy or allogeneic bone marrow
sclerosis; active inflammatory conditions or au
autoimmune thyroiditis requiring hormone re
seropositivity for HIV, HBV, HCV or any other in
(except for stable metastases being treated w
• Uncontrolled medical condition considered as
angina pectoris/myocardial infarction within th
transient ischemic attack within the previous 6
systolic blood pressure ≥180 mmHg
• Estimated life expectancy ≤3 months
• Unable to consent or comply with protocol
• Allergies to any components of the study dru
• Pregnancy or breast feeding
• Concurrent or planned major surgery or likelih
clinical study protocol
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTLA4, Cytotoxic T-
hepatitis B/C virus; HIV, human immunodeficiency virus; MDRD, Modification of Diet in
Criteria In Solid Tumors; ULN, upper limit of normal; WHO, World Health Organization.Hospital Frankfurt in Germany; and University Hospital
Innsbruck in Austria.
Patient recruitment is currently underway in seven
European centers and accrual is expected to take ap-
proximately 18 months. The inclusion and exclusion cri-
teria are listed in Table 3. To investigate the activity of
CV9202 across the spectrum of NSCLC, patients will be
enrolled into one of three study arms based on the histo-
logical and molecular subtype of NSCLC:
 Stratum 1: Patients with non-squamous histology,
without activating EGFR mutations, who achieved
partial response (PR) or stable disease (SD) after at
least four cycles of platinum- and pemetrexed-
based first-line chemotherapy, and with an
indication for maintenance therapy with
pemetrexed.static NSCLC (stage IV)
in size that is eligible for radiation and at least one additional measurable
L, platelet count ≥75000/μL, white blood cell count ≥2000/μL, absolute
t ≥0.8 × 109/L, ALT and AST ≤2.5 times ULN in patients without liver
liver metastases, serum creatinine ≤2 mg/dL, creatinine clearance
cluding vaccination, therapy with anti-CTLA4 antibodies)
the 4 weeks prior to study entry
jections into areas of healthy skin for vaccine injection
rash at time of enrollment)
ntended tumor volume and location to be irradiated
horacic lesions)
transplantation; history of pneumonitis, encephalitis or multiple
toimmune disorders (except for vitiligo, diabetes mellitus type 1 or
placement only), primary or secondary immune deficiency,
fection requiring anti-infection therapy; known brain metastases
ith stereotactic radiation or surgery)
high risk for the treatment with an investigational drug, unstable
e previous 6 months, significant cardiac arrhythmia, stroke or
months, severe hypertension according to WHO criteria, uncontrolled
g
ood of requiring treatment with drugs not permitted by the
Lymphocyte Antigen 4; ECOG, Eastern Cooperative Oncology Group; HBV/HCV,
Renal Disease; NSCLC, non-small cell lung cancer; RECIST, Response Evaluation
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who achieved PR or SD after at least four cycles of
platinum-based and non-platinum compound first-
line chemotherapy.
 Stratum 3: Patients with non-squamous histology
and an activating EGFR mutation, who achieved
PR after up to six months of treatment with an
EGFR TKI.
Study endpoints
The primary endpoint of the study is to determine the
number of patients who experience grade 3 and above
treatment-related adverse events (AEs) according to
NCI-CTCAE, version 4.0 criteria. Secondary endpoints
include determining the incidence of standard clinical
trial clinical and laboratory assessments and evaluating
the cellular and humoural immune responses to antigens
encoded by the six vaccine mRNA components. Further-
more, the presence of humoral immune responses to a
panel of antigens not covered by the vaccine will be eval-
uated to investigate the potential broadening of immune
responses (‘antigen spreading’) following treatment.
Clinical response according to Response Evaluation
Criteria in Solid Tumors (RECIST) criteria (version 1.1)
and assessment of PFS, time to start of second-line can-
cer treatment, response to second-line cancer treatment,
and OS are secondary efficacy endpoints of the study.
Treatment overview
Patients will start screening two weeks after Day 1 of the
last cycle of their first-line chemotherapy (strata 1 and
2) or within six months of starting treatment with an
EGFR TKI (erlotinib or gefitinib) (stratum 3). Patients
will be vaccinated twice (Day 1 and Day 8) with CV9202
before starting radiotherapy on the following day (Day 9;
Figure 1). Each of the six components of CV9202 will be
administered individually as two intradermal injections
(to the inner part of the upper arms or thighs respect-
ively) for a total of 12 injections distributed over the four
limbs. A total dose of 1920 μg mRNA (six compounds ×
320 μg mRNA per compound) will be administered per
vaccination time point.
Patients with non-squamous histology will receive five
vaccinations until Day 57. As the PFS for patients with
squamous histology is expected to be lower than for
patients with non-squamous histology, individuals re-
cruited to strata 2 will receive a more intense vaccin-
ation schedule with six vaccinations until Day 57. A
similar vaccination schedule has also been applied in
other trials testing monotherapy with RNActive vaccines
[23]. Preclinical data indicated that more frequent vacci-
nations enhance the generation of the antigen specific
immune responses which supports the use of the more
intensive schedule in this stratum [CureVac, data onfile]. Vaccine will be administered until disease progres-
sion and the need to start a subsequent systemic
second-line treatment, or occurrence of unacceptable
toxicity requiring treatment discontinuation. It is antici-
pated that approximately six to eight vaccinations will be
administered in strata 1 and 2 (based on an expected
median PFS time of 2–4 months in patients with SD
after the end of first-line combination chemotherapy
[3]), with more vaccinations anticipated for patients in
stratum 3 who have an expected median PFS of at least
9–10 months from the time of start of treatment with
an EGFR TKIs [7-9].
Radiotherapy will be administered in four daily frac-
tions of 5 GY from Day 9 to 12 (Figure 1). Lesions that
are eligible for radiation are those that measure ≥2 cm
in the longest diameter for lymph node lesions or ≥1 cm
for non-lymph node lesions. Eligible lesions will be se-
lected according to the following hierarchy: bone metasta-
ses (first preference); lymph nodes in the paraclavicular,
axillary, or cervical regions; skin or subcutaneous metasta-
ses; and thoracic lesions (only for strata 1 and 2 patients).
A treatment-planning CT scan will be used to define the
macroscopic volume of the selected lesion (gross tumor
volume; GTV), the clinical target volume (CTV; which in-
cludes the GTV with the surrounding tissue, where micro-
scopic tumor involvement is highly probable), and the
planning target volume (PTV; which includes the CTV
with a safety margin for positioning error and dose).
Pemetrexed maintenance treatment (stratum 1) and
the EGFR TKIs erlotinib or gefitinib (stratum 3) will be
administered in accordance with the product label. Pre-
clinical studies have shown that combining pemetrexed,
gefitinib, or erlotinib with RNActive vaccination does
not negatively affect the immune response induced by
RNActive [CureVac, data on file]. Vaccination in stratum
1 will be administered 4–7 days before each scheduled
dose of pemetrexed to provide an interval of at least two
days between vaccination and dexamethasone, which is
given as premedication one day prior to each dose of
pemetrexed.
Assessments
Standard clinical and laboratory safety assessments will
be performed throughout the follow-up period with all
AEs graded according to NCI-CTCAE version 4.0. Radio-
logical tumor assessment will be performed every six
weeks until end of treatment, as recommended for
patients with stage IV NSCLC [49]. In selected patients,
pre- and post-treatment tumor biopsies of non-irradiated
lesions will be collected to evaluate whether the study
treatment induces changes of immune infiltrates in the
tumor and immune signature by gene expression analysis.
Blood samples (peripheral blood mononuclear cells and
serum) for the assessment of humoral and cellular immune
Blood sampling for immunomonitoring /
biomarker analysisVaccination with CV9202
Pemetrexed maintenance
(stratum 1 only)
Stratum 1 – Vaccination with CV9202, 20 GY radiation, pemetrexed maintenance
   Non-squamous cell / No EGFR mutation
   PR or SD after ≥4 cycles first-line platinum + pemetrexed
Day 1 Day 8 Day 15 Day 22
Day 19 Day 61
Day 29 Day 36 Day 43 Day 50 Day 57*
Radiation
(Day 9–12)
Stratum 2 – Vaccination with CV9202, 20 GY radiation
   Squamous cell
   PR or SD after ≥4 cycles first-line platinum + non-platinum
Day 1 Day 8 Day 15 Day 22
Day 19 Day 61
Day 29 Day 36 Day 43 Day 50 Day 57*
Radiation
(Day 9–12)
Stratum 3 – Vaccination with CV9202, 20 GY radiation, continuation of gefitinib or erlotinib
   Non-squamous cell / EGFR mutation
   PR after ≤6 months gefitinib or erlotinib




Day 1 Day 61
Day 29 Day 36 Day 43 Day 50 Day 57*
Radiation
(Day 9–12)
*After Day 57 vaccintion will continue every three weeks until six months from first vaccination, then every six weeks
Figure 1 Study design and treatment schedule. EGFR, epidermal growth factor receptor; PR, partial response; SD, stable disease.
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as humoral responses to additional cancer antigens to
evaluate antigen spreading will be collected at baseline
(Day 1), Day 19, and Day 61. Additional blood samples for
biomarker assessments after the Day 61 visit will be col-
lected every three months. Antibody responses against an-
tigens covered by the vaccine and non-vaccination
antigens will be tested using ELISA or a bead-based assay.
The quality and quantity of preexisting and vaccination-
induced cellular immune responses (antigen-specific T
lymphocytes) to the vaccine will be assessed by multifac-
torial intracellular cytokine staining, measuring CD107a,
IL-2, IFN-gamma and TNF-alpha production by CD4+
and CD8 +T cells, and IFN-gamma ELISpot assay. Vali-
dated protocols (SOPs) and assay-specific response criteria
are in accordance with harmonization panels and guide-
lines of the Immunoguiding Program of the Associationfor Cancer Immunotherapy (CPI/CIMT) and the Cancer
Immunotherapy Consortium of the Cancer Research Insti-
tute (CIC/CRI) [50-56]. Furthermore, a detailed phenotypic
analysis of blood immune cells (B cells, dendritic cells,
myeloid-derived suppressor cells, macrophages, NK cells
and T cells) will be performed by polychromatic flow cy-
tometry. Cytokine/chemokine profiling in the serum sam-
ples of patients will be analyzed by cytometric bead assay.
After the first six patients in a given stratum have
completed radiation, received at least three vaccinations,
and have been monitored for toxicity up to Day 43, re-
cruitment will be interrupted and the safety will be
reviewed by the independent DSMB. If two or more pa-
tients experience treatment-related grade ≥3 AEs, enroll-
ment in the respective stratum will be suspended. If the
DSMB will approve further recruitment, 2–14 additional
patients will be recruited per stratum until a total
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interim safety evaluation assessing the safety of radiation
of thoracic lesions in combination with CV9202 will be
performed in strata 1 and 2 after six patients have
undergone radiation of a thoracic lesion and been evalu-
ated for signs of radiation pneumonitis up to Day 57. If
any patient experiences grade ≥3 radiation pneumonitis,
no further patients will be treated with radiation of thor-
acic lesions.
Statistical considerations
The planned sample size of 36 patients was chosen
based on previous observations with predecessor vac-
cines of CV9202, which indicated that a minimum of
eight patients per stratum would be required to evaluate
the frequency of immune responses. The main statistical
analysis is anticipated six months after enrollment of the
last patient. Safety evaluations will be performed for all
patients receiving at least one dose of study drug (safety
analysis set) and efficacy analyses will be performed in
patients treated as per-protocol. Standard measures will
be used to summarize continuous (mean, standard devi-
ation, and median) and categorical variables (frequencies
and percentages). Time-to-event variables will be analyzed
descriptively by the Kaplan–Meier method and probabil-
ities calculated for specific timepoints (e.g. 12 months or
24 months). All endpoints will be evaluated individually
for the different strata and safety and immune-related
endpoints will be analyzed overall. After completion of
study treatment, all patients will be followed up for sur-
vival every three months until death, withdrawal of in-
formed consent for follow-up, or loss to follow-up. The
follow-up period for all patients will end 18 months after
start of treatment of the last patient enrolled.
Discussion
Despite significant improvements in survival for patients
with stage IV NSCLC over the last few decades, the out-
look for these patients remains bleak. Survival rates
achieved with conventional chemotherapy combinations
have plateaued and median survival in patients with mo-
lecular alteration that can be targeted with novel drugs
is only around 2–3 years [7-9]. Though these targeted
therapies achieve high response rates with prolongation
of PFS, new and well-tolerated therapies are urgently re-
quired. Recruiting the patient’s own immune system into
the therapeutic process through the use of cancer vac-
cines targeted against specific cancer associated antigens
is a promising approach that offers the potential to
change the course of the disease and offer durable and
long-lasting responses [15,57].
Study CV-9202-006 will evaluate the safety and toler-
ability of the RNActive CV9202 vaccine in combination
with radiotherapy. A phase I/IIa trial with a similarmRNA-based vaccine (CV9201; which contains five of
the six antigens in CV9202) in 46 patients with stage III/
IVB NSCLC showed that vaccination was well tolerated
and induced immune responses [23]. Patients received a
maximum total mRNA dose per application of 1600 μg
(320 μg of each individual compound) application and
no dose-limiting toxicities or serious AEs were observed;
only three (7%) patients experienced a Grade ≥3 AE that
was considered potentially treatment related. Antigen-
specific immune responses were seen in over two-thirds of
patients and a significant shift from naïve B-cells to pre-
germinal center B-cells was detected in patients after vac-
cination. Importantly, Treg cell counts did not increase
during treatment. The addition of another mRNA com-
pound encoding the MUC1 antigen in CV9202 will corres-
pond to a 20% increase in mRNA amount per vaccination;
however, based on the dose-escalation experience in the
phase I/IIa trial with CV9104 it is not expected that the
dose of 1920 μg of mRNA in the current trial will signifi-
cantly change the safety profile. Furthermore, vaccination
with MUC1 alone appears to be well tolerated [18-20].
Clinical experience with radiotherapy-vaccine combi-
nations to date is extremely limited. Thirty patients with
localized prostate cancer received a prostate specific
antigen (PSA)-containing poxviral vaccine with radio-
therapy in a randomized phase II trial [58]. This combin-
ation was well tolerated and 13/17 patients treated with
the combination had increased levels of PSA-specific T
cells compared with none of the patients receiving radio-
therapy alone. Low-dose radiotherapy administered con-
comitant with a vector-based carcinoembryonic antigen
vaccine was also well tolerated [59]. In the recent phase III
trial of the MUC1 vaccine BLP25 in patients with NSCLC,
median OS in the total cohort did not significantly
differ between patients randomized to the vaccine or
placebo [19]. However, a clinically meaningful prolonga-
tion of OS was observed in the predefined subgroup of
patients treated with vaccine and concurrent chemo-
radiotherapy compared with placebo and radiotherapy
(30.8 vs 20.6 months, respectively; p = 0.016), whereas
the subgroup of patients receiving a sequential chemo-
radiotherapy did not show a survival difference [19].
As a RNA-based vaccine, CV9202 features several ad-
vantages over other approaches, including vaccination
with peptides, DNA-based vaccines or viral vaccines.
Peptides bind only to certain major histocompatibility
complexes and are therefore only applicable for patients
with certain HLA genotypes; in contrast, there is no
such restriction for RNA-based vaccines, because full
proteins are encoded. In contrast to DNA-based vac-
cines, RNA-based vaccines do not need to cross the nu-
clear membrane to be active and, importantly, in the
absence of reverse transcriptase, RNA cannot be inte-
grated into the genome. Viral-based vaccines may lead
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eign immunogenic virus material, which could override
immune responses against the vaccination antigen.
There is no such risk with RNA-based vaccines. An add-
itional advantage of RNActive vaccines is the potential to
encode a variety of cancer antigens, allowing the induction
of an immune response against multiple antigens, which
limits the risk of tumor escape by antigen loss and induces
relevant immune responses in more patients with different
antigen expression patterns. CV9202 targets three highly
tumor-specific cancer testis antigens which are expressed
in up to 30% of NSCLC tumors [60,61]. In addition, the
antigens survivin, 5 T4 and MUC1 are targeted, which are
all expressed in >90% of NSCLC samples and detected at
low levels in healthy tissues [31-33]. This composition
should maximize the chance that an individual patient’s
tumor will express several of the encoded antigens and
might therefore benefit from vaccination.
One strength of the design of study CV-9202-006 is
that it will investigate the vaccine-radiotherapy com-
bination in three histological/molecular subtypes of
NSCLC, including patients with squamous cell carcin-
oma histology who have a particular need for more
effective therapies. The median OS in patients with
EGFR-mutant advanced NSCLC (represented in strata 3)
is about 2–3 years [7-9]; therefore, these patients will have
received relatively long-term treatment with EGFR TKIs
and achieve a relatively long progression-free period
(estimated at 10 months). This offers a window of oppor-
tunity for testing immunotherapeutic approaches in
NSCLC in these patients, as the vaccine has several
months to induce an immune response while the tumor
growth is still controlled by the TKI. A second strength of
the study design is that the inclusion/exclusion criteria do
not have an upper age restriction; therefore, the patient
population is likely to be representative of the general
population of patients with lung cancer which has a me-
dian age at diagnosis of approximately 70 years [1].
To date, 19 patients have been recruited to study CV-
9202-006 and recruitment is expected to be complete by
the end of 2014. Interim safety analysis of the first six
patients in strata 1 and 2, as well as the first six patients
treated with thoracic radiation, are completed and the
DSMB has approved further recruitment since there
were no safety concerns.
Study sites
This study is to be conducted at the following sites:
 University of Basel, Switzerland
 Johann-Wolfgang-Goethe-Universität, Frankfurt,
Germany
 Kantonsspital St Gallen, Switzerland
 Kantonsspital Graubünden, Chur, Switzerland University Hospital, Innsbruck, Austria
 University Hospital Mainz, Mainz, Germany
 Pius-Hospital Oldenburg, Germany
 HELIOS Klinikum Emil von Behring,
Berlin-Zehlendorf, Germany
 Augusta-Kranken-Anstalt gGmbH, Bochum, Germany
 Klinikum Esslingen GmbH, Esslingen, Germany
 Kliniken der Stadt Köln gGmbH, Cologne, Germany
 Heidelberg University Hospital, Heidelberg, Germany
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